Key result
Cytoreductive surgery in patients with ovarian cancer resulted in a significantly higher loss of intravascular protein compared to patients with benign ovarian tumors (49 g vs 13 g).
Why the study?
Does cytoreductive surgery for ovarian cancer cause greater intraoperative protein shift compared to surgery for benign ovarian tumours?
Population
28 patients undergoing surgery: 15 with benign ovarian tumours and 13 with ovarian cancer
Comparison
Cytoreductive surgery for ovarian cancer vs Surgery for benign ovarian tumours
Design
Cohort
Follow-up
immediately before and after surgery
Authors
Loading...
Greater protein loss may underlie hemodynamic instability in ovarian cancer surgery; this cohort study leaves open causal confirmation.
Observational (n=28)
Does cytoreductive surgery for ovarian cancer cause greater intraoperative protein shift compared to surgery for benign ovarian tumours?
Absolute Event Rate: 49% vs 13%
Patients with ovarian cancer experience significant intraoperative protein shift during cytoreductive surgery, which may explain difficulties in maintaining cardiovascular stability.
Rehm et al. (1998) conducted an observational in Ovarian cancer and benign ovarian tumours (n=28). Cytoreductive surgery for ovarian cancer vs. Cytoreductive surgery for benign ovarian tumours was evaluated on Loss of intravascular protein. Cytoreductive surgery in patients with ovarian cancer resulted in a significantly higher loss of intravascular protein compared to patients with benign ovarian tumors (49 g vs 13 g).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: